Roche launches newborn screening test for three severe genetic conditions
Roche Diagnostics subsidiary TIB MOLBIOL has launched a new screening test that simultaneously detects Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease in newborns.
BERLIN – TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD).
The newly available test provides private and academic hospital laboratories with a ready-to-use solution for early detection of these severe conditions. The aim is to enable clinicians to initiate life-changing treatments sooner, before irreversible symptoms or permanent damage manifest, significantly improving patient outcomes.
Spinal Muscular Atrophy is a rare neuromuscular disorder causing progressive muscle weakness. SCID is a group of genetic disorders where infants lack a functioning immune system, making them highly susceptible to infections. Sickle Cell Disease is an inherited blood disorder that can lead to blood vessel blockages and other serious health complications.
Roche highlights that early diagnosis is crucial for accessing timely and effective treatments. For SMA, early intervention may halt severe nerve damage and prevent permanent disability. For SCID, prompt detection allows for life-saving treatments like bone marrow transplants before dangerous infections occur. Early care for SCD can drastically lower infant mortality.
The LightMix® Newborn TREC/SMN1/HBB kit is designed to run on established LightCycler systems, offering laboratories an integrated solution that can be incorporated into existing workflows.